PARP2 promotes inflammation in psoriasis by modulating estradiol biosynthesis in keratinocytes.


Journal

Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370

Informations de publication

Date de publication:
08 2023
Historique:
received: 05 01 2023
accepted: 12 06 2023
revised: 09 05 2023
medline: 7 8 2023
pubmed: 23 6 2023
entrez: 23 6 2023
Statut: ppublish

Résumé

Poly(ADP-ribose) polymerase 2 (PARP2) alongside PARP1 are responsible for the bulk of cellular PARP activity, and they were first described as DNA repair factors. However, research in past decades implicated PARPs in biological functions as diverse as the regulation of cellular energetics, lipid homeostasis, cell death, and inflammation. PARP activation was described in Th2-mediated inflammatory processes, but studies focused on the role of PARP1, while we have little information on PARP2 in inflammatory regulation. In this study, we assessed the role of PARP2 in a Th17-mediated inflammatory skin condition, psoriasis. We found that PARP2 mRNA expression is increased in human psoriatic lesions. Therefore, we studied the functional consequence of decreased PARP2 expression in murine and cellular human models of psoriasis. We observed that the deletion of PARP2 attenuated the imiquimod-induced psoriasis-like dermatitis in mice. Silencing of PARP2 in human keratinocytes prevented their hyperproliferation, maintained their terminal differentiation, and reduced their production of inflammatory mediators after treatment with psoriasis-mimicking cytokines IL17A and TNFα. Underlying these observations, we found that aromatase was induced in the epidermis of PARP2 knock-out mice and in PARP2-deficient human keratinocytes, and the resulting higher estradiol production suppressed NF-κB activation, and hence, inflammation in keratinocytes. Steroidogenic alterations have previously been described in psoriasis, and we extend these observations by showing that aromatase expression is reduced in psoriatic lesions. Collectively, our data identify PARP2 as a modulator of estrogen biosynthesis by epidermal keratinocytes that may be relevant in Th17 type inflammation. KEY MESSAGES : PARP2 mRNA expression is increased in lesional skin of psoriasis patients. PARP2 deletion in mice attenuated IMQ-induced psoriasis-like dermatitis. NF-κB activation is suppressed in PARP2-deficient human keratinocytes. Higher estradiol in PARP2-deficient keratinocytes conveys anti-inflammatory effect.

Identifiants

pubmed: 37351597
doi: 10.1007/s00109-023-02338-z
pii: 10.1007/s00109-023-02338-z
pmc: PMC10400701
doi:

Substances chimiques

Aromatase EC 1.14.14.1
Imiquimod P1QW714R7M
NF-kappa B 0
PARP2 protein, human EC 2.4.2.30
Poly(ADP-ribose) Polymerase Inhibitors 0
Poly(ADP-ribose) Polymerases EC 2.4.2.30
RNA, Messenger 0
Parp2 protein, mouse EC 2.4.2.30.

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

987-999

Informations de copyright

© 2023. The Author(s).

Références

J Invest Dermatol. 2001 May;116(5):633-40
pubmed: 11348449
J Invest Dermatol. 2011 Mar;131(3):677-87
pubmed: 21085185
J Biol Chem. 2009 Sep 18;284(38):26070-84
pubmed: 19628872
Genes Dev. 2020 Mar 1;34(5-6):341-359
pubmed: 32029454
Life (Basel). 2022 Feb 03;12(2):
pubmed: 35207521
Endocr J. 2016 May 31;63(5):485-93
pubmed: 26888479
J Invest Dermatol. 2014 Jul;134(7):1828-1838
pubmed: 24441097
Annu Rev Immunol. 2014;32:227-55
pubmed: 24655295
Nat Commun. 2015 Jul 03;6:7652
pubmed: 26138368
Prog Lipid Res. 2021 Nov;84:101117
pubmed: 34450194
Allergy. 2011 Jul;66(7):853-61
pubmed: 21276008
Biochem Biophys Res Commun. 1998 Mar 27;244(3):691-5
pubmed: 9535726
Biotechniques. 2007 Jan;42(1):71-5
pubmed: 17269487
Front Immunol. 2022 May 25;13:905239
pubmed: 35693818
J Invest Dermatol. 2018 Jul;138(7):1555-1563
pubmed: 29474945
J Neuroinflammation. 2013 Apr 22;10:49
pubmed: 23607899
J Invest Dermatol. 2019 May;139(5):1110-1117
pubmed: 30684554
Exp Cell Res. 2011 May 15;317(9):1293-300
pubmed: 21300061
J Invest Dermatol. 2009 Jan;129(1):234-8
pubmed: 18633442
Exp Dermatol. 2020 Jan;29(1):79-85
pubmed: 31755591
Arch Dermatol. 2005 May;141(5):601-6
pubmed: 15897382
Nat Commun. 2018 Apr 12;9(1):1420
pubmed: 29650963
Biochim Biophys Acta. 2014 Apr;1842(4):594-602
pubmed: 24365238
J Invest Dermatol. 2019 Jan;139(1):250-253
pubmed: 30077723
J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1085-91
pubmed: 27072912
J Neuroimmunol. 2016 Apr 15;293:45-53
pubmed: 27049561
Int J Womens Dermatol. 2015 May 14;1(2):104-107
pubmed: 28491968
Clin Exp Dermatol. 2001 Jun;26(4):314-20
pubmed: 11422182
J Invest Dermatol. 2001 Jul;117(1):74-80
pubmed: 11442752
J Immunol. 2006 Nov 1;177(9):6489-96
pubmed: 17056581
Endocr Rev. 2007 Aug;28(5):521-74
pubmed: 17640948
Lab Invest. 2005 Oct;85(10):1250-62
pubmed: 16127429
J Immunol. 2010 May 1;184(9):5029-37
pubmed: 20351193
Immunology. 2004 Dec;113(4):509-17
pubmed: 15554929
J Biol Chem. 2006 Aug 25;281(34):24138-48
pubmed: 16798734
Endocrinology. 2000 Sep;141(9):3403-11
pubmed: 10965913
Int J Dermatol. 2003 Jul;42(7):518-20
pubmed: 12839599
J Invest Dermatol. 2010 May;130(5):1213-26
pubmed: 19812592
J Biol Chem. 2002 Jun 21;277(25):23028-36
pubmed: 11948190
J Steroid Biochem Mol Biol. 2013 Sep;137:107-23
pubmed: 23435015
J Invest Dermatol. 2010 Nov;130(11):2629-37
pubmed: 20613774
J Invest Dermatol. 2021 Feb;141(2):458-462.e3
pubmed: 32621824
Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14573-14582
pubmed: 31266892
J Immunotoxicol. 2016 Nov;13(6):885-896
pubmed: 27602995
Curr Opin Immunol. 2007 Jun;19(3):281-6
pubmed: 17433650
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Nov;1863(11):1399-1412
pubmed: 30077797
Biomed J. 2015 May-Jun;38(3):194-205
pubmed: 26068028
J Invest Dermatol. 2017 Jul;137(7):1474-1483
pubmed: 28259685
Immunity. 2012 Jul 27;37(1):74-84
pubmed: 22727489
Genes Dev. 2020 Mar 1;34(5-6):321-340
pubmed: 32029456

Auteurs

Dóra Antal (D)

Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem ter 1., Elettudomanyi Epulet, H-4032, Debrecen, Hungary.
The Hungarian Academy of Sciences, Center of Excellence, Budapest, Hungary.

Ágnes Pór (Á)

Department of Pathology, Gyula Kenézy Campus, Clinical Centre, University of Debrecen, Debrecen, Hungary.

Ilona Kovács (I)

Department of Pathology, Gyula Kenézy Campus, Clinical Centre, University of Debrecen, Debrecen, Hungary.

Katalin Dull (K)

Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Szilárd Póliska (S)

Genomic Medicine and Bioinformatics Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Gyula Ujlaki (G)

Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem ter 1., Elettudomanyi Epulet, H-4032, Debrecen, Hungary.
The Hungarian Academy of Sciences, Center of Excellence, Budapest, Hungary.

Máté Ágoston Demény (MÁ)

Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem ter 1., Elettudomanyi Epulet, H-4032, Debrecen, Hungary.
The Hungarian Academy of Sciences, Center of Excellence, Budapest, Hungary.

Attila Gábor Szöllősi (AG)

Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Borbála Kiss (B)

Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Andrea Szegedi (A)

Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
ELKH-DE Allergology Research Group, University of Debrecen, Debrecen, Hungary.

Péter Bai (P)

Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem ter 1., Elettudomanyi Epulet, H-4032, Debrecen, Hungary.
The Hungarian Academy of Sciences, Center of Excellence, Budapest, Hungary.
NKFIH-DE Lendület Laboratory of Cellular Metabolism, Debrecen, Hungary.
Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
MTA-DE Cell Biology and Signaling Research Group ELKH, Debrecen, Hungary.

Magdolna Szántó (M)

Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem ter 1., Elettudomanyi Epulet, H-4032, Debrecen, Hungary. mszanto@med.unideb.hu.
The Hungarian Academy of Sciences, Center of Excellence, Budapest, Hungary. mszanto@med.unideb.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH